MINNEAPOLIS, MN, US, Feb. 10, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc., in collaboration with its wholly-owned subsidiary PetVivo Animal Health (OTCQX: PETV; OTCID: PETVW), a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, today announced that it is retracting and replacing its previously issued press release dated February 9, 2026 regarding the Company’s fiscal third quarter 2026 conference call. This press release supersedes in it ...

MINNEAPOLIS, MN, US, Feb. 09, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc., including its wholly-owned subsidiary Petvivo Animal Health, Inc. (OTCQX: PETV; OTCID: PETVW), a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, will hold a conference call on Monday, February 16, 2026 at 5:00 p.m. Eastern time to discuss results for the fiscal third quarter ended December 31, 2025. The financial results will be issued in a press release prior t ...

Core Insights - PetVivo Animal Health, Inc. has received formal acknowledgment from Health Canada for its product Spryng® with OsteoCushion® Technology as a veterinary medical device, marking a significant milestone in the company's global commercialization strategy [1][2][3] Company Overview - PetVivo Holdings, Inc. operates as an emerging biomedical device company focused on innovative medical technologies for companion animals and equine athletes, leveraging human therapies for animal treatment in a capital-efficient manner [6][7] - The company has a robust pipeline of products, including Spryng® and PrecisePRP®, protected by twelve patents and six trade secrets [7] Product Details - Spryng is an intra-articular injectable device designed to support joint health and manage lameness and other joint-related issues in animals [2][4] - The product is currently available in the United States and through select international distribution partners, with plans for commercial availability in Canada anticipated in the second quarter of 2026 [4][3] Regulatory Milestone - The acknowledgment from Health Canada serves as an important endorsement of the company's scientific and regulatory strategy, reflecting its commitment to providing innovative solutions for animal health [3][4] - Despite the regulatory acknowledgment, Spryng is not expected to be immediately available in Canada due to ongoing infrastructure development and operational requirements [3]

Core Insights - PetVivo Holdings, Inc. has launched PetVivo.ai, an AI platform aimed at transforming the $150 billion pet care market by significantly reducing customer acquisition costs for veterinary practices [1][3][4] - The company is shifting from traditional medical device sales to a high-margin AI Software-as-a-Service (SaaS) model, which offers recurring revenue and scalability [2][5] Industry Context - The pet care industry exceeds $150 billion annually, with Gen Z and Millennial pet owners making up 57% of all pet owners, who expect modern digital experiences [3] - Veterinary practices currently rely on outdated marketing methods, leading to high customer acquisition costs ranging from $80 to $400 per new client [3][4] Company Strategy - PetVivo.ai utilizes nine specialized AI agents to connect veterinary practices with engaged pet parents, generating qualified leads at a cost of $3 per pet parent, compared to traditional methods costing $15 to $45 [4][6] - The platform's beta program showed that the median practice acquired 47 new clients over six months at a blended customer acquisition cost of $42.53, achieving significant savings [4][6] Financial Metrics - The platform is expected to achieve gross margins of 80-90% and a lifetime value to customer acquisition cost (LTV/CAC) ratio of 25:1 [6] - Projections indicate that by Year 1, the company could reach $12 million in annual recurring revenue (ARR) with 500 practices, scaling to $360 million ARR with 10,000 practices by Year 5 [6] Market Opportunity - PetVivo.ai targets approximately 30,000 U.S. veterinary practices and over 100,000 globally, with strong scaling potential even under conservative adoption forecasts [5][6] - The launch is seen as a catalyst for re-evaluating the company's valuation, transitioning from traditional medical device revenue multiples of 1-2x to AI SaaS multiples of 15-30x [5][7] Competitive Advantages - PetVivo.ai holds a first-mover advantage with no direct AI competitors and strong two-sided network effects, supported by existing relationships with 1,200 veterinary clinic distributors [7] - Deep integrations with practice management systems are expected to facilitate adoption and reduce onboarding friction [7] Commercial Launch - Following successful beta testing, PetVivo.ai is now fully commercial with open sign-ups, offering a 14-day free trial and three pricing tiers [8]

Core Insights - PetVivo Holdings, Inc. will hold a conference call on November 14, 2025, to discuss its fiscal second quarter results for the period ending September 30, 2025 [1][2] - The company focuses on innovative medical devices and therapeutics for companion animals, leveraging human therapies for efficient treatment [4] - PetVivo has a strong product pipeline, including SPRYNG with OsteoCushion technology and PrecisePRP, both currently available for commercial sale [5] Company Overview - PetVivo Holdings, Inc. operates through its subsidiary PetVivo Animal Health, Inc., specializing in biomedical devices for companion animals [4] - The company aims to bring veterinary medical devices to market faster than more regulated pharmaceuticals, enhancing revenue timelines [4] - PetVivo holds a portfolio of twelve patents and six trade secrets protecting its biomaterials and products [5] Upcoming Events - The conference call will include a presentation by management followed by a Q&A session [2] - Dial-in information for the conference call includes a toll-free number and a specific conference ID and passcode [2] - A replay of the conference call will be available on the company's website [3]

Core Insights - PetVivo Holdings, Inc. has appointed Josh Ruben to its Board of Directors, enhancing its leadership team with expertise in healthcare finance and corporate strategy [1][2][4] - Ruben's background includes significant experience in executing multi-billion-dollar mergers and acquisitions, which will support PetVivo's growth and market expansion efforts [2][4] - The company focuses on innovative medical therapeutics for companion animals, particularly in treating osteoarthritis and joint conditions [2][6] Company Overview - PetVivo Holdings, Inc. operates in the biomedical device sector, specifically targeting the commercialization of medical devices and therapeutics for companion animals [6] - The company aims to leverage human therapies for animal treatment, allowing for a quicker market entry compared to traditional pharmaceuticals [6] - PetVivo has a diverse product pipeline, including its lead product SPRYNG, which utilizes OsteoCushion technology for joint-related afflictions in animals [7] Leadership and Strategy - Josh Ruben, as the Managing Director of Life Sciences at Trinity Capital, brings a wealth of experience in venture lending and investment banking, particularly in life sciences [4][5] - His expertise will be instrumental in guiding PetVivo's capital strategy and maximizing value creation across veterinary and emerging human applications [5] - The company holds a portfolio of twelve patents and six trade secrets, protecting its innovative biomaterials and production processes [7]

Core Insights - Medtronic plc (NYSE:MDT) is recognized as the world's largest manufacturer of biomedical devices and implantable technologies, operating through four primary divisions: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes [2]. Group 1: Price Target and Market Outlook - Stifel raised its price target on Medtronic from $90.00 to $105.00 while maintaining a Hold rating, following a visit to the company's HUGO robotic facility [3]. - The company is reportedly "confidently ready" to introduce its HUGO robotic system in the US, pending expected FDA approval by the end of fiscal 2026 [3]. - Medtronic's strong financial position enhances its prospects for expansion [3]. Group 2: HUGO Robotic System Development - Investors were provided with a detailed look at the HUGO system's development, including live demonstrations of Medtronic's digital ecosystem technologies [4]. - The company plans to adopt "a deliberate and thoughtful approach" for the introduction of the HUGO system to the US market after receiving FDA approval [4]. Group 3: Dividend Appeal - Medtronic's dividend adds to its investment appeal, as the company is close to achieving Dividend King status with 48 consecutive years of dividend increases [5].

Core Insights - PetVivo Holdings, Inc. has entered into note conversion agreements with four existing shareholders to convert $2,018,155 of outstanding promissory notes into 3,669,806 shares of common stock, effectively eliminating over $2 million of debt from its balance sheet [1][4] Group 1: Financial Developments - The total outstanding debt consisted of a principal amount of $1,850,000 and accrued interest of $168,155 [1] - The conversion prices of the notes ranged from $0.50 to $0.75 per share [1] - The successful completion of the note conversion strengthens the company's financial position and allows for more resources to be directed towards product commercialization [4] Group 2: Product Information - PetVivo's signature products include SPRYNG with OsteoCushion Technology, an injectable veterinary medical device that aids in managing joint pain and restoring joint mechanics [2][7] - PrecisePRP is a first-in-class, off-the-shelf platelet-rich plasma product designed for intra-articular administration in dogs and horses, providing a consistent dose of 4 billion platelets per vial [3][7] Group 3: Company Overview - PetVivo Holdings, Inc. focuses on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for companion animals [6] - The company has a robust pipeline of products protected by twelve patents and six trade secrets [7]

Core Viewpoint - PetVivo Holdings, Inc. is set to present at the Life Sciences Virtual Investor Forum on September 18, 2025, highlighting its innovative medical devices and therapeutics for animals [1][4]. Company Overview - PetVivo Holdings, Inc. is an emerging biomedical device company focused on the commercialization of medical devices and therapeutics for horses and companion animals [5]. - The company aims to leverage human therapies for animal treatment in a capital and time-efficient manner, with a strategy that allows for accelerated revenue timelines compared to pharmaceuticals [5]. Product Information - PetVivo has a robust pipeline of products, including SPRYNG™ with OsteoCushion™ technology for managing joint-related afflictions in animals and PrecisePRP, a first-in-class platelet-rich plasma product [6]. - The company holds a portfolio of twelve patents and six trade secrets that protect its biomaterials and production processes [6]. Event Details - The Life Sciences Virtual Investor Forum will take place on September 18, 2025, from 11:00 to 11:30 am ET, allowing real-time interaction between investors and the company [2]. - Archived webcasts will be available for those unable to attend the live event [2].

Core Points - PetVivo Holdings, Inc. will hold a conference call on August 14, 2025, to discuss its fiscal first quarter results for the period ending June 30, 2025 [1][2] - The company focuses on innovative medical devices and therapeutics for companion animals, leveraging human therapies for efficient treatment [4] - PetVivo has a strong product pipeline, including SPRYNG with OsteoCushion technology and PrecisePRP, both currently available for commercial sale [5] Company Overview - PetVivo Holdings, Inc. operates through its subsidiary, PetVivo Animal Health, Inc., and is dedicated to the manufacturing, commercialization, and licensing of biomedical devices for animals [4] - The company holds a portfolio of twelve patents and six trade secrets that protect its biomaterials and products [5] Conference Call Details - The conference call will take place at 5:00 p.m. Eastern time, with a toll-free dial-in number provided for participants [2] - A replay of the conference call will be available on the company's website [3]